TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 150 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $674,291 | -45.1% | 75,424 | -5.7% | 0.00% | -50.0% |
| Q2 2023 | $1,228,616 | -31.9% | 79,988 | -0.2% | 0.00% | -33.3% |
| Q1 2023 | $1,803,136 | +19.2% | 80,175 | +11.5% | 0.00% | +50.0% |
| Q4 2022 | $1,512,288 | -12.9% | 71,911 | +2.0% | 0.00% | -33.3% |
| Q3 2022 | $1,737,000 | -0.2% | 70,504 | -1.8% | 0.00% | 0.0% |
| Q2 2022 | $1,740,000 | -6.7% | 71,802 | -0.7% | 0.00% | +50.0% |
| Q1 2022 | $1,864,000 | -23.4% | 72,330 | -7.8% | 0.00% | -33.3% |
| Q4 2021 | $2,434,000 | +32.0% | 78,416 | +3.1% | 0.00% | +50.0% |
| Q3 2021 | $1,844,000 | +57.2% | 76,030 | -5.5% | 0.00% | +100.0% |
| Q2 2021 | $1,173,000 | -43.7% | 80,425 | -3.6% | 0.00% | -66.7% |
| Q1 2021 | $2,084,000 | +3.3% | 83,458 | +12.7% | 0.00% | 0.0% |
| Q4 2020 | $2,018,000 | – | 74,039 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |